FDA-cleared Monarch Platform Featured in Xconomy

Operated by a hand-held controller, Auris Health’s recently FDA-cleared Monarch Platform has lung cancer as its first targeted disease state. According to the article, the FDA determined the technology Auris built was equivalent to other bronchoscopic procedures that use endoscopy to examine a patient’s lungs. However, with the integration of the latest advancements in robotics, software, data science, and endoscope innovation, Auris aims to go further than conventional endoscopy.

Excerpt from the article:
"Though lung cancer is Auris’s first target, co-founder and CEO Frederic Moll said in a prepared statement that the company envisions applying the technology to other endoscopic procedures in the future."